1-Isopropyl-4-(2,2,2-trifluoroethyl)benzene | 1099597-44-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 1-Isopropyl-4-(2,2,2-trifluoroethyl)benzene
• 英文别名: 1-propan-2-yl-4-(2,2,2-trifluoroethyl)benzene
• CAS: 1099597-44-0
• 化学式: C₁₁H₁₃F₃
• 分子量: 202.22
• InChiKey: DXHDYTBEGUNHQV-UHFFFAOYSA-N

物化性质

• 沸点：
  187.6±40.0 °C(Predicted)
• 密度：
  1.071±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR TRAITER DES ÉTATS ASSOCIÉS À UNE ACTIVITÉ DE STING
  申请人：IFM DUE INC

  公开号：WO2020252240A1

  公开（公告）日：2020-12-17

  This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

  本公开涉及抑制（例如，拮抗）干扰素基因激活因子（STING）的化学实体（例如，化合物或药用可接受的盐，和/或水合物，和/或共晶，和/或化合物的药物组合）。所述化学实体是有用的，例如，用于治疗在受试者（例如，人）中增加（例如，过量）STING激活（例如，STING信号传导）有助于病理和/或症状和/或进展的状况、疾病或失调（例如，癌症）。本公开还涉及含有相同成分的药物组合物以及使用和制备相同成分的方法。
• [EN] BROAD SPECTRUM ANTI-CANCER COMPOUNDS<br/>[FR] COMPOSÉS ANTICANCÉREUX À LARGE SPECTRE
  申请人：UNIV CALIFORNIA

  公开号：WO2021076617A1

  公开（公告）日：2021-04-22

  Described herein, inter alia, are compounds for treating cancer and methods of use. This disclosure features chemical entities (e.g., small hairpin RNAs (shRNAs), micro RNA (miRNAs), small interfering RNA (siRNAs), small molecule inhibitors, antisense nucleic acids, peptides, viruses, CRISPR-sgRNAs, or combinations thereof) that inhibit one or more of m6A writers (e.g., methyltransferase like 3 (Mettl3 or MT-A70) or methyltransferase like-14 (Mettl14)), m6Am writers (e.g., phosphorylated CTD interacting factor I (PCIF 1), or Mettl3/14), m6A erasers (e.g., fat-mass and obesity-associated protein (FTO) or ALKB homolog 5 (ALKBH5)), m6Am erasers (e.g., FTO), m6A readers (e.g., YTH domain-containing family proteins (YTHs)), YTF domain family member 1 (YTHDF 1), YTF domain family member 2 (YTHDF 2), YTF domain family member 3 (YTHDF 3), or tyrosine-protein phosphatase non-receptor type 2 (PTPN2).

  本文描述了用于治疗癌症的化合物和使用方法。该公开涉及抑制m6A编写酶（例如，甲基转移酶类3（Mettl3或MT-A70）或甲基转移酶类14（Mettl14））、m6Am编写酶（例如，磷酸化CTD相互作用因子I（PCIF 1）或Mettl3/14）、m6A擦除酶（例如，脂肪质量和肥胖相关蛋白（FTO）或ALKB同源物5（ALKBH5））、m6Am擦除酶（例如，FTO）、m6A读取器（例如，YTH结构域含家族蛋白（YTHs））、YTF结构域家族成员1（YTHDF 1）、YTF结构域家族成员2（YTHDF 2）、YTF结构域家族成员3（YTHDF 3）或酪氨酸蛋白磷酸酶非受体型2（PTPN2）等化学实体（例如，小发夹RNA（shRNAs）、微RNA（miRNAs）、小干扰RNA（siRNAs）、小分子抑制剂、反义核酸、肽、病毒、CRISPR-sgRNAs或其组合）。
• SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR
  申请人：Noble Stewart A.

  公开号：US20090029971A1

  公开（公告）日：2009-01-29

  Compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.

  本发明揭示了作为过氧化物酶体增殖物活化受体调节剂的化合物，包括这些化合物的制药组合物和使用它们治疗疾病的方法。
• MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS
  申请人：Hadida Ruah Sara S.

  公开号：US20130296364A1

  公开（公告）日：2013-11-07

  Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

  本发明的化合物及其药学上可接受的组合物可用作ATP结合盒（“ABC”）转运蛋白或其片段的调节剂，包括囊性纤维化跨膜传导调节因子（“CFTR”）。本发明还涉及使用本发明的化合物治疗ABC转运蛋白介导的疾病的方法。
• MATTER OF COMPOSITION, SYNTHESIS, FORMULATION AND APPLICATION OF FL118 PLATFORM POSITIONS 7 AND 9-DERIVED ANALOGUES FOR TREATMENT OF HUMAN DISEASE
  申请人：Canget BioTekpharma

  公开号：US20200231596A1

  公开（公告）日：2020-07-23

  Described herein, are the chemical synthesis, matter of compositions, formulation, function, methods and uses of the FL118 platform Positions 7 and/or 9-derived analogues for treating cancer or other human diseases. Compounds derived from chemical modifications of the FL118 platform are employed alone or in combination with other anti-cancer agents to preclude, eliminate or reverse cancer phenotypes. This invention intends to realize unique personalized cancer treatment (personalized precision medicine) through application of a series of structural relevant individual FL118 platform-derived analogues, which target multiple cellular human disease-relevant proteins and their signaling pathways.